EGFR and metastatic colorectal cancer: Subsequently, anti-EGFR monoclonal antibodies (mAbs) were developed, particularly cetuximab and panitumumab, and these have changed the treatment landscape for many patients with metastatic colorectal cancer (mCRC) [3].